• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs Original Articles
Conclusions— In HPS2-THRIVE, the addition of extended-release niacin–laropiprant to statin-based therapy reduced quality of life–adjusted survival and increased hospital costs. Clinical Trial Registration— URL: http://clinicaltrials.gov. Unique identifier: NCT00461630.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Kent, S., Haynes, R., Hopewell, J. C., Parish, S., Gray, A., Landray, M. J., Collins, R., Armitage, J., Mihaylova, B., on behalf of the HPS2-THRIVE Collaborative Group Tags: Cardiovascular Disease, Treatment, Cost-Effectiveness, Quality and Outcomes, Vascular Disease Original Articles Source Type: research

Abstract 146: Clinical and Economic Consequences of Statin Intolerance in the U.S.: Results from an Integrated Health System Session Title: Poster Session I
Conclusion: While the majority of SI patients were on a statin, SI patients demonstrate a higher risk of some cardiovascular events; incur higher healthcare costs; and difficulty reaching LDL-C goals compared to patients without SI. Alternative treatment strategies are needed to better serve this at-risk patient population.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Sanchez, R. J., Graham, J. H., Evans, M. A., Mallya, U. G., Panaccio, M. P., Steinhubl, S. R. Tags: Session Title: Poster Session I Source Type: research

Abstract 251: Risk Factors for Recurrence of Cardiovascular Events Following Acute Coronary Syndrome: Longitudinal Analysis from 2006-2011 Poster Session III
Conclusion: Following an ACS event, patients with pre-admission statin use or a prior CABG had decreased risk, while older patients or those with baseline comorbidities had increased risk of an adverse CV event occurring sooner. Ultimately, identifying high-risk ACS subgroups may facilitate tailored and more aggressive treatment to improve outcomes.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Reddy, V. S., Luthra, R., Xu, Y., Wilhelm, K., Power, T. P., Fisher, M. D., Cziraky, M. J. Tags: Poster Session III Source Type: research